Lipid Profile Normalization Effect of Hunteria Umbellata Aqueous Fruit Extract in Wistar Rats Induced with Aloxan Monohydrate
Main Article Content
Abstract
The present study investigated the potential effect of Hunteria Umbellata fruit extract on lipid profile reduction administered at different daily doses ie 200mg/kg, 400mg/kg compared with control (1) and group5 treated at 0.3ml standard drug insulin following aloxan monohydrate induction. The lipid profile- HDL,LDL,vLDL,Triglycerides and Total cholesterol were determine using precipitant (mmol), enzymatic hydrolysis, enzymatic and point methods. Results from this study indicate that the lipid profile reduction potential of H.U fruit extract was most effective in group2 administered 200mg/kg body weight with no aloxan induction. This was closely followed by group3 treated at 400mg/kg and group5 treated with the standard drug insulin after aloxan induction compared with the control. However, goup4 induced with aloxan and treated at 200mg/kg body weight has an elevated lipid profile compared with the control and other groups studied. Findings from this study have shown that moderate dose intake of Hunteria umbellata fruit extract by subjects with hyperlipidaemia can be beneficial in the reduction of lipid profile but the rapidity of its reduction rate is dose dependent.
Article Details
This work is licensed under a Creative Commons Attribution 4.0 International License.
References
I. Adejuwon Adewale Adeneye, Olufunmilayo Olaide Adeyemi and Esther Oluwatoyin Agbaje (2010).Anti-obesity and antihyperlipidaemic effect of Hunteria umbellata seed extract in experimental hyperlipidaemia. Journal of Ethnopharmacology 130(2):307-314
II. Adejuwon AA and Peter AC (2015).Weight losing,antihyperlipidemic and cardioprotective effects of the alkaloid fraction of Hunteria umbellata seed extract on normal and triton-induced hyperlipidemic rats.Asian Pacific Journal of Tropical Biomedicine. Volume 5(5):387-394
III. Ajiboye TO, Hussaini AA, Nafiu BY, Ibitoye OB. (2017). Aqueous seed extract of Hunteria umbellata (K. Schum.) Hallier f. (Apocynaceae) palliates hyperglycemia, insulin resistance, dyslipidemia, inflammation and oxidative stress in high-fructose diet-induced metabolic syndrome in rats. J Ethnopharmacol. 198:184-193.
IV. Casula M, Colpani O, Xie S, Catapano AL, Baragetti A (2021). "HDL in Atherosclerotic Cardiovascular Disease: In Search of a Role". 10 (8): 1869.
V. Charles NN, Solomon MU, Kiridi Emily GE (2023). Renal profile of aloxan-induced diabetic wistar rats treated with Hunteria umbellata fruit extract. Scientific Research Journal of Medical Sciences. 1(1):10-16.
VI. Deng S, Xu Y, Zheng L (2022). "HDL Structure". Adv Exp Med Biol. Advances in Experimental Medicine and Biology. 1377: 1–11
VII. Gerhard Whitworth and Eleesha Lockett (2018). Should You Be Worried If Your Triglycerides Are Low?https://www.healthline.com/health/low-triglycerides
VIII. Ighodaro Igbe, Gerald Ikechi Eze and Oghenekevwe Ojameruaye (2013). Sub- acute Toxicity of Aqueous Fruit Pulp Extract of Hunteriaumbellata in Albino Wistar Rats. Niger. J. Physiol. Sci. 28; 077 –082
IX. Incardona JP, Eaton S (2000). "Cholesterol in signal transduction". Current Opinion in Cell Biology. 12 (2): 193–203.
X. Ivanova EA, Myasoedova VA, Melnichenko AA, Grechko AV, Orekhov AN (2017). "Small Dense Low-Density Lipoprotein as Biomarker for Atherosclerotic Diseases". Oxidative Medicine and Cellular Longevity. 2017 (10): 1273042.
XI. Kiridi Emily GE, Solomon MU,Charles NN (2022).Hematological restoration effect of Hunteria umbellata fruit extract on phenylhydrazine induced anemia in wistar rats. Gph-International Journal of Applied Science. 05 (12):01-13
XII. Lampe, MA, Burlingame AL,Whitney J,Williams ML, Brown BE, Roitman E, Elias M (1983). "Human stratum corneum lipids: characterization and regional variations". J. Lipid Res. 24 (2): 120–130.
XIII. Madsen CM, Varbo A, Nordestgaard BG (2017). "Extreme high high-density lipoprotein cholesterol is paradoxically associated with high mortality in men and women: two prospective cohort studies". Eur Heart J. 38 (32): 2478–2486.
XIV. Nelson, D L.; Cox, MM. (2000). Lehninger, Principles of Biochemistry (3rd ed.). New York: Worth Publishing. ISBN 1-57259-153-6.
XV. Peterson MM, Mack JL, Hall PR, et al. (2008). "Apolipoprotein B Is an innate barrier against invasive Staphylococcus aureus infection". Cell Host & Microbe. 4 (6): 555–66
XVI. Pirahanchi, Yasaman; Sinawe, Hadeer; Dimri, Manjari (2022). "Biochemistry, LDL Cholesterol", StatPearls, Treasure Island (FL): StatPearls Publishing, PMID 30137845, retrieved 2022-12-26
XVII. Sadava D, Hillis DM, Heller HC, Berenbaum MR (2011). Life: The Science of Biology 9th Edition. San Francisco: Freeman. pp. 105–114.
XVIII. Santulli G, Jankauskas SS, Gambardella J (2021). "Inclisiran: a new milestone on the PCSK9 road to tackle cardiovascular risk". Eur Heart J Cardiovasc Pharmacother. 7 (3): e11–e12
XIX. Solomon MU, Azibalua AA, Kiridi Emily GE, Alagha Bibi-Welson E (2021).Total Serum cholesterol and selected electrolytes during pregnancy among women residents in Yenagoa metropolis, Bayelsa state Nigeria. The Journal of Medical Research 7 (6):191-194
XX. Solomon MU, Bonnie KG, Tabowei OC, Ngaikedi FCN (2017).The serum cholesterol and blood pressure of selected adults in Bayelsa state Nigeria.Eurpean Journal of pharmaceutical and medical research. 7 (6):191-194.
XXI. Superko HR, Nejedly M, Garrett B (2002). "Small LDL and its clinical importance as a new CAD risk factor: a female case study". Progress in Cardiovascular Nursing. 17 (4): 167–73.
XXII. Trimarco V, Izzo R, Morisco C, Mone P, Maria Virginia M, Falco A, Pacella D, Gallo P, Lembo M, Santulli G, Trimarco B (2022). "High HDL (High- Density Lipoprotein) Cholesterol Increases Cardiovascular Risk in Hypertensive Patients". Hypertension. 79 (10): 2355–2363.
XXIII. Yu Si y,Tu DL,Zhi HZ,(2020).Mechanisms underlying direct actions of hyperlipidaemia on myocardium:an updated review PMCID:PMC 7007679/PMID:32035485.s
XXIV. Zhang, Da-Wei; Garuti, Rita; Tang, Wan-Jin; Cohen, Jonathan C.; Hobbs, Helen H. (2008-09-02). "Structural requirements for PCSK9-mediated degradation of the low-density lipoprotein receptor". Proceedings of the National Academy of Sciences of the United States of America. 105 (35): 13045–13050.